<DOC>
	<DOCNO>NCT00671112</DOCNO>
	<brief_summary>RATIONALE : Everolimus bortezomib may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose everolimus give together bortezomib treat patient relapsed refractory lymphoma .</brief_summary>
	<brief_title>Everolimus Bortezomib Treating Patients With Relapsed Refractory Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose everolimus ( 10 mg PO daily ) combination bortezomib patient relapsed/refractory indolent mantle cell non-Hodgkin 's lymphoma ( NHL ) include cutaneous form , relapsed/refractory aggressive NHL ineligible hematopoetic stem cell transplantation Secondary - Evaluate toxicity combination . - Assess pharmacokinetics interaction agent . - Assess response rate 6-month progression-free survival treat patient . - Obtain preliminary data ass association tumor characteristic response treatment . subject underwent biopsy prior study treatment . OUTLINE : This dose-escalation study . Patients receive bortezomib IV day 1 , 4 , 8 , 11 . Patients also receive oral everolimus daily every day day 1-21 course . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients undergo blood sample collection Cycle 1 , Day 11 pharmacokinetic study . Baseline tumor expression mTOR NFkB -related protein ( i.e. , pS6K , pAKT , cREL ) FOXP3 assess immunohistochemistry .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Able provide voluntary write informed consent , understanding consent may withdraw subject time without prejudice future medical care . Diagnosed relapsed refractory NHL , limit subtypes list . The subject must histologic information diagnosis accord review Cleveland Clinic Foundation , either initial diagnosis subsequent relapse . ( Biopsy require relapse , suggest . Biopsy outside institution , review Cleveland Clinic , acceptable . ) `` Relapsed refractory '' refers patient receive least 1 prior treatment regimen lymphoma ( may include prior autologous stem cell transplantation ) demonstrate evidence progressive disease clinical and/or radiographic characteristic . `` Indolent lymphoma '' include , refers small lymphocytic lymphoma/Bcell chronic lymphocytic leukemia ( SLL/CLL ) ; lymphoplasmacytic lymphoma ( without Waldenstrom 's macroglobulinemia ) ; hairy cell leukemia ; follicular lymphoma ( FL ) grade ; marginal zone Bcell lymphoma ; mantle cell lymphoma . Transformed lymphoma include patient ineligible ( refuse ) hematopoetic stem cell transplant . In addition , cutaneous B T cell lymphoma permit . Cutaneous T cell lymphoma must refractory 1 prior systemic therapy ( topical therapy , photopheresis , radiation consider systemic therapy ) . Transformed B T cell cutaneous lymphoma also permit . Relapsed/refractory diffuse large B cell lymphoma ( DLBCL ) allow patient eligible , refuse , hematopoetic stem cell transplant . Relapsed/refractory nodal , leukemic , extranodal T cell lymphoma eligible . Subtypes eligible include anaplastic large cell lymphoma , angioimmunoblastic T cell lymphoma , PTCLNOS , nasal disseminate extranodal T/NK lymphoma , enteropathyassociated T cell lymphoma , hepatosplenic gamma/delta T cell lymphoma , subcutaneous panniculitislike T cell lymphoma , Tprolymphocytic leukemia , Adult Tcell leukemia/lymphoma , large granular lymphocytic leukemia , aggressive NK leukemia . Plasma cell myeloma Hodgkin lymphoma exclude . Prior therapy bortezomib allow . Patients receive prior bortezomib therapy must receive bortezomib &gt; 6 month ago , must show response . Patients respond prior bortezomib therapy eligible . Measurable disease one following : radiographic criterion ( ≥2 cm compute tomography ) ; lymphoma involve peripheral blood 5000 leukemia cells/mm3 , degree bone marrow infiltration bone marrow biopsy . Skin involvement without nodal bone marrow involvement permit cutaneous lymphoma also permit . ( see section 6.0 , Measurement Effect ) . Eastern Cooperative Group ( ECOG ) Performance Status 02 . Serum bilirubin level ≤1.5 time upper limit normal ( ULN ) range laboratory . Higher level acceptable attribute active hemolysis ineffective erythropoiesis . Serum AST serum ALT level must ≤2.5 x ULN , ≤5 x ULN patient liver involvement lymphoma . Must adequate bone marrow function : Absolute neutrophil count ( ANC ) ≥1,000/uL Platelet count ( Plt ) ≥ 75,000/uL Hemoglobin ( Hgb ) ≥ 9.0 g/dL Must adequate renal function : Creatinine ≤ 1.5 X ULN . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 7 day start study drug . In addition , sexually active WCBP must agree use adequate contraceptive method ( tubal ligation ; intrauterine device ; barrier contraceptive spermicide ) study . Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , therefore consider effective study . WCBP must agree pregnancy test every 4 week study drug . Male subject agrees use acceptable method contraception duration study . Female patient : Are postmenopausal least 1 year Screening visit , OR Are surgically sterile , OR If childbearing potential , agree practice 2 effective method contraception , time , time signing inform consent 30 day last dose study treatment , OR agree completely abstain heterosexual intercourse Male patient , even surgically sterilize ( ie , status postvasectomy ) , : Agree practice effective barrier contraception entire study treatment period 30 day last dose study treatment , OR Agree completely abstain heterosexual intercourse Able adhere study visit schedule protocol requirement . Prior treatment investigational drug , chemotherapy , monoclonal antibody within precede 1 month Chronic treatment systemic steroid another immunosuppressive agent . Patients receive immunization attenuate live vaccine study period . History allogeneic stem cell transplantation . Any patient know diabetes mellitus currently require insulin therapy , patient preexist diabetes mellitus poor control , define hemoglobin A1C ( HbA1C ) value 9 % within 4 week start therapy Fasting serum cholesterol &gt; 300 mg/dL OR &gt; 7.75 mmol/L fast triglyceride &gt; 2.5 x ULN . NOTE : In case one threshold exceed , patient include initiation appropriate lipid lower medication . Uncontrolled brain leptomeningeal metastasis , include patient continue require glucocorticoid brain leptomeningeal metastasis . Other malignancy within past 3 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin , lowrisk prostate cancer curative therapy . Patients severe and/or uncontrolled medical condition condition could affect participation study : unstable angina pectoris , history congestive heart failure , history know myocardial infarction , uncontrolled cardiac arrhythmia severely impaired lung function uncontrolled diabetes define fast serum glucose &gt; 1.5x ULN , medication active ( acute chronic ) uncontrolled infection/ disorder . nonmalignant medical illness uncontrolled whose control may jeopardize treatment study therapy liver disease include know history viral hepatitis B C , evidence cirrhosis , chronic active hepatitis chronic persistent hepatitis know history HIV seropositivity Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption RAD001 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) Patients active , bleed diathesis Breast feeding pregnant females Patients know hypersensitivity everolimus rapamycins ( sirolimus , temsirolimus ) excipients , bortezomib , boron , mannitol History noncompliance medical regimens Patients unwilling unable reason ( personal , medical , psychiatric ) comply protocol Patients preexist peripheral neuropathy grade ≥ 2 eligible Patients take concomitant medication ( chronically within 1 week study drug administration ) strong inhibitor hepatic metabolism via P450/CY3PA4 isoenzyme exclude . Patients receive hematopoietic growth factor ( filgrastim , pegfilgrastim , sargramostim ) within 28 day first dose screening . Patient myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen must document investigator medically relevant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>Waldenstrom 's macroglobulinemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>hairy cell leukemia</keyword>
	<keyword>cutaneous B T cell lymphoma</keyword>
	<keyword>transform lymphoma</keyword>
	<keyword>transform B T cell cutaneous lymphoma</keyword>
	<keyword>relapsed refractory diffuse large B cell lymphoma</keyword>
	<keyword>extranodal T cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T cell lymphoma</keyword>
	<keyword>PTCL-NOS</keyword>
	<keyword>nasal disseminate extranodal T/NK lymphoma</keyword>
	<keyword>enteropathy-associated T cell lymphoma</keyword>
	<keyword>hepatosplenic gamma/delta T cell lymphoma</keyword>
	<keyword>subcutaneous panniculitis-like T cell lymphoma</keyword>
	<keyword>T-prolymphocytic leukemia</keyword>
	<keyword>adult T-cell leukemia/lymphoma</keyword>
	<keyword>large granular lymphocytic leukemia</keyword>
	<keyword>aggressive NK leukemia</keyword>
</DOC>